{"id":"W2987820141","doi":"10.1097/md.0000000000017748","title":"Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer","year":2019,"lang":"en","type":"review","venue":"Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Office of the Chief Medical Examiner","funders":"National Key Research and Development Program of China; Department of Science and Technology of Sichuan Province; National Natural Science Foundation of China","keywords":"Medicine; Enzalutamide; Prostate cancer; Hazard ratio; Adverse effect; Internal medicine; Randomized controlled trial; Urology; Oncology; Abiraterone; Cancer; Confidence interval; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0168071,0.0007335659,0.004909299,0.002082041,0.0002345671,0.001459156,0.0009214283,0.001121013,0.002948801],"category_scores_gemma":[0.02992372,0.0003451119,0.005697916,0.00201768,0.0007488732,0.000953892,0.0005021699,0.001460791,0.0002693307],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001101625,"about_ca_system_score_gemma":0.002176145,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001021936,"about_ca_topic_score_gemma":0.002121212,"domain_scores_codex":[0.9869087,0.006612169,0.003718455,0.0006837736,0.00190394,0.0001729716],"domain_scores_gemma":[0.97701,0.01414829,0.007175451,0.0003542534,0.001048558,0.0002634342],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.04158892,0.0004521431,0.006031669,0.6116059,0.07985151,0.0001774259,0.0001964201,0.0007889706,0.001550157,0.0007391124,0.002549076,0.2544687],"study_design_scores_gemma":[0.1007874,0.03815328,0.05626069,0.3046238,0.4326511,0.001911937,0.0004635269,0.001589487,0.003609054,0.00347677,0.05627794,0.0001950246],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01213851,0.9855278,0.0002568396,0.0005243638,0.0002083401,0.0002572358,0.0002737762,0.00001174813,0.0008014503],"genre_scores_gemma":[0.2747759,0.7189952,0.001888591,0.0016404,0.0009330002,0.0008323519,0.0005928921,0.0000171211,0.0003245535],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.0168071,"threshold_uncertainty_score":0.08888549,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1090050402307738,"score_gpt":0.4317681291000279,"score_spread":0.3227630888692541,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}